Non-resectable slow-growing meningiomas treated by hydroxyurea

David Loven*, Ruth Hardoff, Zvi Bar Sever, Adam P. Steinmetz, Michael Gornish, Zvi H. Rappaport, Eyal Fenig, Zvi Ram, Aaron Sulkes

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Purpose: To test the benefit of hydroxyurea in the treatment of recurrent and non-resectable slow-growing meningiomas. Methods: Twelve patients with regrowing non-malignant meningiomas, were enrolled for a protocol of 2 years with continuous chemotherapy with hydroxyurea, 20 mg/kg/day. Response to treatment was evaluated both clinically and by diagnostic imaging using computed tomography (CT) and 201-Thallium single photon emission CT. One minimal response was documented by CT, accompanied by clinical stabilization. Nine patients showed progressive disease, at least by one imaging procedure, with a median time to progression of 13 months (range 4-24). Two other patients were not available for response due to early removal from the study, following abrupt manifestation of grades 3-4 hematological toxicity. Conclusion: In this series hydroxyurea has not shown effectiveness in the treatment of non-resectable slow-growing meningiomas: neither for achieving response, nor for arresting disease progression.

Original languageEnglish
Pages (from-to)221-226
Number of pages6
JournalJournal of Neuro-Oncology
Issue number1-2
StatePublished - Mar 2004
Externally publishedYes


  • Chemotherapy
  • Hydroxyurea
  • Meningioma
  • Slow-growing tumor
  • Thallium-SPECT


Dive into the research topics of 'Non-resectable slow-growing meningiomas treated by hydroxyurea'. Together they form a unique fingerprint.

Cite this